Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May;22(5):581-583.
doi: 10.1016/S1470-2045(21)00155-8. Epub 2021 Apr 1.

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Barliz Waissengrin  1 , Abed Agbarya  2 , Esraa Safadi  3 , Hagit Padova  4 , Ido Wolf  5
Affiliations

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

Barliz Waissengrin et al. Lancet Oncol. 2021 May.

Erratum in

  • Correction to Lancet Oncol 2021; 22: 581-83.
    [No authors listed] [No authors listed] Lancet Oncol. 2021 Jun;22(6):e239. doi: 10.1016/S1470-2045(21)00264-3. Epub 2021 Apr 30. Lancet Oncol. 2021. PMID: 33939964 Free PMC article. No abstract available.
No abstract available

PubMed Disclaimer

Conflict of interest statement

IW and BW contributed to conception and design of the study. BW, AA, ES, and HP contributed to collection and analysis of data. BW and IW contributed to data analysis and interpretation. All authors contributed to writing of the Comment and approved the final version before submission. This study had no funding. BW reports speaker fees and fees for consultancy from MSD. AA reports speaker fees and fees for consultancy from MSD, Roche, Boehringer Ingelheim, AstraZeneca, Eli Lilly, Pfizer, Bristol Meyers Squibb, Novartis, Merck Serono, Sanofi, Oncotest-Teva, Medison, AbbVie, and Takeda; grants from Altman Health; and is a member of the board for the Israeli Lung Cancer Advocacy Group. IW reports speaker fees and fees for consultancy from Roche, Bristol Myers Squibb, MSD, and Novartis, and research funding from Roche and MSD. ES and HP declare no competing interests. No individual participant-level data will be shared.

Figures

Figure
Figure
Systemic side-effects after the second dose of the BNT162b2 mRNA vaccine among patients with cancer treated with immune checkpoint inhibitors and matched controls ICI=patients with cancer treated with immune checkpoint inhibitors. Bars show the proportion of participants reporting on each side-effect. Differences between the groups were calculated using the χ2 test.
See this image and copyright information in PMC

References

    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med. 2020;383:2603–2615. - PMC - PubMed
    1. Harel A. Israel's ambitious vaccine drive is set for success as Netanyahu seeks election campaign boost. Haaretz. Dec 29, 2020. https://www.haaretz.com/israel-news/.premium-israel-s-ambitious-vaccine-...
    1. Venkatesulu BP, Chandrasekar VT, Girdhar P, et al. A systematic review and meta-analysis of cancer patients affected by a novel coronavirus. medRxiv. 2020 doi: 10.1101/2020.05.27.20115303. published online May 29. (preprint). - DOI - PMC - PubMed
    1. Giannakoulis VG, Papoutsi E, Siempos II. Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Glob Oncol. 2020;6:799–808. - PMC - PubMed
    1. Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395:1907–1918. - PMC - PubMed

MeSH terms